These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36472057)
1. A Focus on Long-Term Follow-Up of Immunoprophylaxis to Recurrent Urinary Tract Infections: 10 Years of Experience with MV140 Vaccine in a Cohort of 1003 Patients Support High Efficacy and Safety. Ramírez Sevilla C; Gómez Lanza E; Llopis Manzanera J; Cetina Herrando A; Puyol Pallàs JM Arch Esp Urol; 2022 Nov; 75(9):753-757. PubMed ID: 36472057 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and health cost analysis between immunoprophylaxis with MV140 autovaccine, MV140 vaccine and continuous treatment with antibiotics to prevent recurrent urinary tract infections. Ramírez-Sevilla C; Gómez-Lanza E; Llopis-Manzanera J; Cetina-Herrando A; Puyol-Pallàs JM Actas Urol Esp (Engl Ed); 2023; 47(1):27-33. PubMed ID: 36470711 [TBL] [Abstract][Full Text] [Related]
3. Impact of whole-cell bacterial immunoprophylaxis in the management of recurrent urinary tract infections in the frail elderly. Lorenzo-Gómez MF; Padilla-Fernández B; Flores-Fraile J; Valverde-Martínez S; González-Casado I; Hernández JD; Sánchez-Escudero A; Vicente Arroyo MJ; Martínez-Huélamo M; Criado FH; Blanco-Tarrío E; Márquez-Sánchez M; Flores-Fraile MC; Saz-Leal P; Mirón-Canelo JA; García-Perdomo HA; García-Cenador MB Vaccine; 2021 Oct; 39(42):6308-6314. PubMed ID: 34538523 [TBL] [Abstract][Full Text] [Related]
4. Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. Lorenzo-Gómez MF; Foley S; Nickel JC; García-Cenador MB; Padilla-Fernández BY; González-Casado I; Martínez-Huélamo M; Yang B; Blick C; Ferreira F; Caballero R; Saz-Leal P; Casanovas M NEJM Evid; 2022 Apr; 1(4):EVIDoa2100018. PubMed ID: 38319200 [TBL] [Abstract][Full Text] [Related]
5. Immunoactive Prophylaxis Protocol of Uncomplicated Recurrent Urinary Tract Infections in a Cohort of 1104 Women Treated with Uromune Ramírez Sevilla C; Gómez Lanza E; Puyol Pallàs M Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672735 [TBL] [Abstract][Full Text] [Related]
7. Secondary Analysis of Interstitial Cystitis/Bladder Pain Syndrome Patients Enrolled in a Recurrent Urinary Tract Infection Prevention Study Provides a Novel Paradigm for Etio-Pathogenesis and Practical Management of This Infection Phenotype. Nickel JC; Cotechini T; Doiron RC Pathogens; 2024 May; 13(5):. PubMed ID: 38787248 [TBL] [Abstract][Full Text] [Related]
8. Reducing Recurrent Urinary Tract Infections in Women with MV140 Impacts Personal Burden of Disease: Secondary Analyses of a Randomized Placebo-controlled Efficacy Study. Curtis Nickel J; Foley S; Yang B; Casanovas M; Caballero R; Diez-Rivero CM; Lorenzo-Gómez MF Eur Urol Open Sci; 2024 May; 63():96-103. PubMed ID: 38585593 [TBL] [Abstract][Full Text] [Related]
9. A Combination of Polybacterial MV140 and Martin-Cruz L; Sevilla-Ortega C; Benito-Villalvilla C; Diez-Rivero CM; Sanchez-Ramón S; Subiza JL; Palomares O Front Immunol; 2020; 11():612269. PubMed ID: 33552074 [TBL] [Abstract][Full Text] [Related]
10. Case report: Long-term follow-up of patients who received a FimCH vaccine for prevention of recurrent urinary tract infections caused by antibiotic resistant Enterobacteriaceae: a case report series. Perer E; Stacey H; Eichorn T; Hughey H; Lawrence J; Cunningham E; Johnson MO; Bacon K; Kau A; Hultgren SJ; Hooton TM; Harris JL Front Immunol; 2024; 15():1359738. PubMed ID: 38545110 [TBL] [Abstract][Full Text] [Related]
16. Long-term antibiotics for preventing recurrent urinary tract infection in children. Williams G; Craig JC Cochrane Database Syst Rev; 2019 Apr; 4(4):CD001534. PubMed ID: 30932167 [TBL] [Abstract][Full Text] [Related]
17. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Bauer HW; Alloussi S; Egger G; Blümlein HM; Cozma G; Schulman CC; Eur Urol; 2005 Apr; 47(4):542-8; discussion 548. PubMed ID: 15774256 [TBL] [Abstract][Full Text] [Related]
18. MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Benito-Villalvilla C; Cirauqui C; Diez-Rivero CM; Casanovas M; Subiza JL; Palomares O Mucosal Immunol; 2017 Jul; 10(4):924-935. PubMed ID: 27966556 [TBL] [Abstract][Full Text] [Related]
19. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Bleidorn J; Hummers-Pradier E; Schmiemann G; Wiese B; Gágyor I Ger Med Sci; 2016; 14():Doc01. PubMed ID: 26909012 [TBL] [Abstract][Full Text] [Related]
20. The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study. Anesi JA; Lautenbach E; Nachamkin I; Garrigan C; Bilker WB; Omorogbe J; Dankwa L; Wheeler M; Tolomeo P; Han JH; BMC Infect Dis; 2019 Feb; 19(1):163. PubMed ID: 30764770 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]